Skyrizi (guselkumab) is a fully human monoclonal antibody that targets the p19 subunit of interleukin‑23. Because it’s a protein drug, its “stay‑in‑body” time is governed by its half‑life, not by a simple “on‑off” switch.
| Parameter | Typical value for guselkumab |
|-----------|-----------------------------|
| Half‑life | ≈ 28 days (4 weeks) |
| Time to reach steady‑state | ~ 6–8 weeks after the first dose (after the loading doses) |
| Time to fall below therapeutic levels | Roughly 5–6 half‑lives → 6–7 months after the last injection |
| Clinical effect window | The anti‑psoriatic benefit can last for 8–12 weeks between doses, and the drug is usually given every 8 weeks once maintenance therapy has begun. |
What does that mean for you?
1. After the initial loading doses (Week 0, 4, and 16 in the label), your body will gradually accumulate guselkumab until it reaches a steady plasma concentration around Week 8–12.
2. Between maintenance doses (every 8 weeks thereafter), the drug remains at therapeutic levels. If you miss a dose, levels will drop gradually, roughly 1 day per week.
3. If you stop therapy, the drug will slowly clear, taking about 6–7 months for it to fall below the threshold considered “therapeutic.” During that time it may still exert some pharmacologic effect.
Things that can change the numbers
- Body weight – heavier patients sometimes have a slightly longer apparent half‑life.
- Renal or hepatic impairment – doesn’t usually alter the half‑life dramatically because the drug is catabolized by normal protein‑degrading pathways.
- Concurrent medications that affect immune complex clearance – rare, but possible.
- Individual immune response – some people clear antibodies faster.
Bottom line
- Half‑life: ~ 4 weeks.
- Therapeutic effect: maintained for 8–12 weeks with regular dosing.
- After stopping: expect the drug to clear in about 6–7 months, but it may still have lingering effects for weeks or months.
If you’re planning a treatment change, or have concerns about how long Skyrizi stays in your body, discuss with your prescribing clinician. They can tailor the dosing schedule or monitor drug levels if needed.